Umoja Biopharma has announced the closing of an oversubscribed $100m Series C financing round, which will enable the company to progress its in vivo chimeric antigen receptor (CAR)-T cell therapy pipeline. Double Point Ventures and DCVC Bio jointly led the round, with...
Kyverna Therapeutics, under new CEO Warner Biddle, has refined its strategic focus for its CAR-T cell therapy program, KYV-101, prioritizing stiff person syndrome (SPS) as its initial target for approval. Here’s a summary: New Strategic Focus: Kyverna aims to be...
US-based biotech company A2 Biotherapeutics (A2 Bio) has secured $80m in funding to advance its pipeline of chimeric antigen receptor (CAR)-T cell therapies for solid tumour cancers. The Series C financing, backed by investors such as The Column Group and Samsara...
The results of a preclinical study by lymphoma researchers at Weill Cornell Medicine suggest that an emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies. EZH2 enzyme activity in tumor cells is...
Cartesian Therapeutics reported longer-term results from a mid-stage study of its mRNA CAR-T therapy for myasthenia gravis, suggesting that the therapy is durable beyond the initial three-month study period. In 12 patients, the mean decrease at six months in a...
